Capital Management Corp VA Sells 41,191 Shares of Harmony Biosciences Holdings, Inc. $HRMY

Key Points

• Capital Management Corp VA sold 41,191 shares of Harmony Biosciences in Q4, trimming its stake by 12.8% to 281,721 shares (about 0.49% of the company) valued at roughly $10.54 million, making HRMY its 25th-largest holding and 1.7% of its portfolio.
• Harmony reported Q4 EPS of $0.38, missing the $0.84 consensus while revenue rose 21.1% year-over-year to $243.78 million (slightly above estimates); the stock trades near $31.83 with a $1.84 billion market cap and a P/E of 11.75.
• Wall Street sentiment is mixed — several firms cut ratings and targets (Bank of America to $28, UBS to $36) though HC Wainwright keeps a $55 buy; the consensus rating is 'Hold' with an average price target of $42.67.

Capital Management Corp VA decreased its holdings in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 12.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 281,721 shares of the company's stock after selling 41,191 shares during the period. Harmony Biosciences accounts for 1.7% of Capital Management Corp VA's portfolio, making the stock its 25th largest position. Capital Management Corp VA owned approximately 0.49% of Harmony Biosciences worth $10,542,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Robeco Institutional Asset Management B.V. increased its stake in shares of Harmony Biosciences by 0.6% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 47,085 shares of the company's stock valued at $1,762,000 after purchasing an additional 298 shares in the last quarter. Thrivent Financial for Lutherans increased its stake in shares of Harmony Biosciences by 1.2% during the third quarter. Thrivent Financial for Lutherans now owns 28,639 shares of the company's stock valued at $789,000 after purchasing an additional 348 shares in the last quarter. Nebula Research & Development LLC increased its position in shares of Harmony Biosciences by 2.0% during the second quarter. Nebula Research & Development LLC now owns 17,403 shares of the company's stock valued at $550,000 after acquiring an additional 348 shares in the last quarter. Amalgamated Bank increased its position in shares of Harmony Biosciences by 3.8% during the third quarter. Amalgamated Bank now owns 11,328 shares of the company's stock valued at $312,000 after acquiring an additional 417 shares in the last quarter. Finally, Profund Advisors LLC increased its position in shares of Harmony Biosciences by 5.1% during the third quarter. Profund Advisors LLC now owns 10,803 shares of the company's stock valued at $298,000 after acquiring an additional 520 shares in the last quarter. Institutional investors own 86.23% of the company's stock.

Harmony Biosciences Trading Up 1.8%

Shares of HRMY stock opened at $31.83 on Friday. Harmony Biosciences Holdings, Inc. has a 12-month low of $25.52 and a 12-month high of $40.87. The company has a current ratio of 3.60, a quick ratio of 3.58 and a debt-to-equity ratio of 0.17. The firm's 50 day moving average is $28.76 and its 200 day moving average is $32.87. The stock has a market capitalization of $1.84 billion, a P/E ratio of 11.75, a P/E/G ratio of 0.43 and a beta of 0.97.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its earnings results on Tuesday, February 24th. The company reported $0.38 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.84 by ($0.46). Harmony Biosciences had a return on equity of 19.86% and a net margin of 18.29%.The company had revenue of $243.78 million during the quarter, compared to analysts' expectations of $240.04 million. During the same quarter in the prior year, the business posted $0.85 EPS. The company's revenue for the quarter was up 21.1% compared to the same quarter last year. Research analysts expect that Harmony Biosciences Holdings, Inc. will post 3.34 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on HRMY. Bank of America reduced their price target on shares of Harmony Biosciences from $32.00 to $28.00 and set an "underperform" rating for the company in a research report on Wednesday, February 25th. UBS Group reduced their price target on shares of Harmony Biosciences from $46.00 to $36.00 and set a "neutral" rating for the company in a research report on Wednesday, February 25th. Weiss Ratings downgraded shares of Harmony Biosciences from a "hold (c)" rating to a "hold (c-)" rating in a research report on Wednesday. Truist Financial downgraded shares of Harmony Biosciences from a "buy" rating to a "hold" rating in a research report on Monday, February 23rd. Finally, HC Wainwright reissued a "buy" rating and set a $55.00 price target on shares of Harmony Biosciences in a research report on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have given a Hold rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $42.67.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company's mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company's flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.

Want to see what other hedge funds are holding HRMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.